Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The PA criteria differ by diagnosis: For Type 2 diabetes indication: Documented Type 2 diabetes diagnosis (A1C 6.5% or fasting glucose 126 mg/dL) BMI 27 kg/m (this requirement appears in most UnitedHealthcare medical policies even for diabetes, though not an FDA requirement) Trial and failure of metformin for at least 90 days, unless contraindicated Trial and failure of at least one other oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days A1C remains 7.0% despite conventional therapy For obesity indication (when covered): BMI 30 kg/m, or BMI 27 kg/m with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) Documented weight-loss attempts with behavioral modification and diet for at least 6 months No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2) Prescriber must be MD, DO, NP, or PA (some plans require endocrinologist or bariatric specialist) The PA approval timeline is 3 to 7 business days for standard requests, 24 hours for urgent requests
All attendees will benefit from insights shared by a diverse group of speakers, including FDA officials, industry leaders, and renowned academics
Scientific interest in 5-Amino-1MQ comes from the research into NNMT biology and its contribution to cellular metabolism
Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions
GLP-1s in the news Most recent: Weight Loss Drugs Like Ozempic Are Lowering the U.S
Personalized treatment protocols should be developed in consultation with a qualified physician and a homeopathic practitioner.
